Medicare AdvantagePrior AuthMedium impact
MA08.183a, Zenocutuzumab-zbco (Bizengri®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Summary
MA08.183a updates medical necessity criteria for Zenocutuzumab-zbco (Bizengri®), a new pharmacy agent. This is a recent policy change (1 month old) affecting Medicare Advantage coverage and prior authorization requirements for this medication. Billing teams must implement new medical necessity documentation and authorization workflows to ensure claim approval.
Action Required
By 2026-05-25: Billing and prior authorization teams must review the full MA08.183a policy text at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=06&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#medicare-advantage-ma08-183a-zenocutuzumab-zbco-bizengri to identify specific medical necessity criteria. Update authorization request templates and provider education materials with the new criteria. Train billing staff and providers on documentation requirements for Bizengri® claims. Implement prior authorization workflow in billing system before June 1, 2026. Claims submitted without meeting medical necessity criteria will be denied.